ECHOSENS

FDA Accepts First Non-Invasive Surrogate Endpoint for MASH Clinical Trials

- The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials. - This milestone could replace invasive liver biopsies for patient enrollment and treatment response assessment in MASH drug development programs. - The acceptance is supported by over 5,600 peer-reviewed publications and endorsements from major pharmaceutical companies including Eli Lilly, Boehringer Ingelheim, and Novo Nordisk. - The development has the potential to accelerate drug development by improving trial recruitment and patient retention while reducing patient burden.